Symbol | Exchange | Currency |
|---|
Personalis (PSNL): Q2 GAAP EPS of -$0.34 beats by $0.05.Revenue of $21.67M (+11.1% Y/Y) beats by $0.46M.The company expects the following for FY 2021:Total revenue to be...
By Chris Wood Stephen’s note: Today, I’m passing the reins to my friend Chris Wood, our in-house microcap stock expert. A couple months ago, Chris revealed his microcap “incubator”...
Personalis (NASDAQ:PSNL): Q1 GAAP EPS of -$0.29 beats by $0.07.Revenue of $20.88M (+9.0% Y/Y) beats by $0.45M.Press Release
We expect Zomedica ZOM investors to focus on the outlook for the company’s first commercial product, scheduled to be launched on Mar 30, 2021, when it reports fourth-quarter...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Sell | Buy | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 144.84 | 144.90 | 143.51 | +1.08 | +0.75% | 67.62M | NASDAQ | |||
| 2,827.40 | 2,834.40 | 2,815.10 | +4.3 | +0.15% | 1.51M | NASDAQ | |||
| 324.76 | 329.07 | 322.51 | -3.77 | -1.15% | 21.37M | NASDAQ | |||
| 144.61 | 144.85 | 142.79 | +1.22 | +0.85% | 3.17M | NYSE | |||
| 69.66 | 70.38 | 69.47 | +0.04 | +0.06% | 4.12M | NYSE | |||
| 230.63 | 234.00 | 229.03 | -1.76 | -0.76% | 484.94K | NYSE | |||
| 42.74 | 43.55 | 42.69 | -0.19 | -0.44% | 918.77K | NYSE | |||
| 16.22 | 16.36 | 16.22 | +0.03 | +0.19% | 5.04M | NASDAQ | |||
| 166.61 | 167.17 | 164.14 | +3.14 | +1.92% | 13.90M | NYSE | |||
| 218.62 | 219.31 | 216.62 | +1.16 | +0.53% | 22.37M | NASDAQ | |||
| 158.81 | 159.66 | 157.51 | -0.45 | -0.28% | 4.29M | NASDAQ | |||
| 628.29 | 639.42 | 625.16 | -5.51 | -0.87% | 4.10M | NASDAQ | |||
| 55.55 | 55.99 | 55.47 | +0.20 | +0.36% | 7.11M | NYSE | |||
| 52.27 | 52.81 | 52.01 | +0.35 | +0.67% | 26.65M | NYSE | |||
| 3.81 | 4.06 | 3.81 | -0.140 | -3.54% | 40.98K | NASDAQ |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.